Please login to the form below

Not currently logged in
Email:
Password:

Kite

This page shows the latest Kite news and features for those working in and with pharma, biotech and healthcare.

Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA

Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA

The site, situated in the US, is set to produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancers. ... strengthen our ability to meet the needs of people living with difficult-to-treat blood cancers,” said Christi Shaw, CEO of Kite.

Latest news

More from news
Approximately 24 fully matching, plus 72 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene

  • Deal Watch October 2018

    Gilead’s subsidiary, Kite, has agreed a deal for a research collaboration with HiFiBiO Therapeutics, the Hong Kong-based company which is working on the discovery of therapeutic antibodies through single

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... Spark has signed a marketing deal with Novartis in Europe, which means the big pharma company will set the

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Understanding the evolving CAR-T market

    Big pharma also wanted a slice of the action. Aggressive deal-making quickly became central to the rise of CAR-T, with Gilead acquiring Kite Pharma for a mammoth $11.9bn

  • Training the next generation of biotech leaders

    In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....